Improved biotech stock performance translated into an uptick in public financings, but private money and partnership dollars slipped. Excluding partnership monies, industry raised $6.9 billion in public equity and debt financings, an increase of 61% over 1Q16. Although private money dipped from a 1Q16 peak of $4 billion to $3.1 billion, it is still on course for its best-ever year. Partnership money ($13.1 billion) declined for the third consecutive quarter, representing a 24% drop from 1Q16.

Stock market performance

Global biotech initial public offerings

Global biotech venture capital investment

Global biotech industry financing

Notable 2Q16 deals